-
Interim PET results identify aggressive NHL patients who would benefit from intensive therapy
Time of Update: 2023-02-03
The researchers who performed post-hoc analysis of the PETAL trial first used the PET data of the PETAL test to investigate whether the average FDG uptake value of lymphoma lesions predicted the patient's time to progression (TTP); Second, it investigated whether comprehensive iPET analysis could identify subgroups of patients who would benefit from intensive therapy.
-
Hainan released the world's first full-cycle industrial support policy for digital therapeutics, with 21 measures to build an industrial highland
Time of Update: 2022-10-20
On October 11, Hainan Province issued the "Several Measures for Hainan Province to Accelerate the Development of the Digital Therapy Industry" (hereinafter referred to as the "Measures"), which put f
-
Lancet Oncol: Bemarituzumab combined with mFOLFOX6 is promising for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma
Time of Update: 2022-10-19
This is a randomized, double-blind, placebo-controlled phase 2 trial (FIGHT) that recruited patients aged 18 years and older with HER2-positive, FGFR2b-selected gastric or gastric-oesophageal junction adenocarcinoma from 17 countries and excluded patients who had previously received selective inhibitors of the FGF-FGFR pathway.
-
Haier Biomedical Centrifuge Free Trial 3 Months Activity is in Full Swing
Time of Update: 2022-09-14
Let the country's well-known universities, cutting-edge institutions, etcAll praised the approved Haier centrifugesDon't you want to experience it?Haier Biomedical Sends Benefits!Haier centrifuges are free to try for 3 months of activityThe heat is ongoingFirst come, first served!Event period: July 1 to September 30Participation form: Scan the following QR code to joinScan the code to register for a free trial
-
Blood: Treatment of B-ALL in Children and Young Adults with CD19/22 CAR T Cells
Time of Update: 2022-08-19
The limited CAR T cell expansion and persistence of MSCV-CD19.
The limited CAR T cell expansion and persistence of MSCV-CD19.
The limited CAR T cell expansion and persistence of MSCV-CD19.
The limited CAR T cell expansion and persistence of MSCV-CD19.
-
NEJM: Addition of pembrolizumab before and after surgery significantly improves survival in early-stage triple-negative breast cancer
Time of Update: 2022-03-04
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab combined with chemotherapy, plus postoperative adjuvant pembrolizumab, significantly improved event-free productivity compared with neoadjuvant chemotherapy alone .
For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab combined with chemotherapy, plus postoperative adjuvant pembrolizumab, significantly improved event-free productivity compared with neoadjuvant chemotherapy alone .
-
Ann Oncol: Phase III BROCADE3 Study Shows Veliparib (Veliparib) Plus Carboplatin/Paclitaxel After Veliparib Maintenance Therapy Improves Outcomes in Patients With BRCA1/2 Germline Mutated Breast
Time of Update: 2022-03-04
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
The phase III BROCADE3 study showed that adding veliparib to carboplatin/paclitaxel improved PFS in patients with advanced HER2-negative, BRCA1/2 germline-mutated breast cancer (HR=0.
-
In vivo gene editing achieves another breakthrough, first children's clinical results released
Time of Update: 2021-11-16
The design of LB-001 uses an AAV vector to precisely insert a transgene expressing methylmalonyl-CoA mutase (MMUT) into the albumin gene locus of liver cells .
-
Professor Song Yuqin 76.8
Time of Update: 2021-09-30
Compared with the global CAR-T research data, the one-year OS rate of the RELIANCE study is the highest, which proves the long-term survival benefits of the use of Recchio Lunsai injection and brings hope to the treatment of hematological tumors .
-
Cancer Sci: Aletinib can effectively and safely treat relapsed or refractory ALK-positive lymphoma
Time of Update: 2021-06-10
An open-label phase II trial aims to study the efficacy and safety of the second-generation ALK inhibitor aletinib in patients with relapsed or refractory ALK-positive asexual large cell lymphoma (ALCL).
-
Janssen/Legendary Bio-CAR-T Therapy Completes Rolling Submission of FDA Biological Products License Application
Time of Update: 2021-04-13
A few days ago, Legendary Biotech stated in the regulatory documents submitted to the US SEC that the company’s partner Janssen has completed the rolling submission to the US FDA for the B-cell maturation antigen (BCMA) CAR-T therapy ciltacabtagene autoleucel ( cilta-cel) Biologics License Application (BLA) for the treatment of adult patients with relapsed/refractory multiple myeloma.
-
The FDA approved a new authorization for emergency use of coronary antibody therapy
Time of Update: 2020-12-16
However, a few days later, the National Institutes of Allergy and Infectious Diseases, part of the National Institutes of Health, said in a statement on October 26th that more careful studies had shown that the treatment was not a safety issue but was less effective for hospitalized patients.
-
Domestic 1 class of new drugs outbreak! In two weeks 25 varieties were approved clinically
Time of Update: 2020-11-14
September 12 - September 25, Hengrui a total of two new class 1 drugs were approved clinically, respectively, injection with Karelli pearl monoanti, SHR-1701 injection, of which carelli pearl monoantigen is a humanized anti-PD-1 monoclonal antibody, has been approved Hodgkin lymphoma, advanced hepatocellular cancer, advanced esophageal squamous and non-small cell lung cancer four adaptation.
-
Why is the world's first new crown vaccine approved for sale, but people do not agree
Time of Update: 2020-09-03
August 11, Russian President Vladimir Putin announced that Russia's first new crown vaccine, Satellite V, had been registered with the state, saying that "the vaccine is very effective, has a stable immunity and has passed all tests"; According to Russian Health Minister Mlaashko, the vaccine's Phase III clinical trial began on the 12th and will last about five months, noting that the vaccine is expected to make inoculators immune to the new coronavirus for up to two years.
-
Treatment of specific non-small cell lung cancer German Merck MET inhibitors identified as breakthrough therapy
Time of Update: 2020-06-17
Lung cancer is the most common cancer and one of the world's most serious causes of cancer death Every year, 2 million patients are diagnosed with lung cancer, and 1.7 million die from lung cancer In
